A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors (IMAG1NE)

A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 (MAGE-A1-Directed TCR-Transduced Autologous CD8+ T-cells) in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic, MAGE-A1+ Solid Tumors That Either Have No Further Approved Therapeutic Alternative(s) or Are Not Eligible for Them or Are in a Non- Curable State and Have Received a Minimum of Two Lines of Systemic Therapy

The aim of this study is to determine the safety, tolerability and anti-tumoral activity of autologous T cells transduced with a T cell receptor specific for MAGE-A1 in eligible patients with advanced solid tumors.

Study Overview

• Status: Terminated
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Biological: Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR

Detailed Description

This is a Phase 1/2, first-in-human, open-label, accelerated titration, two-part clinical trial of TK-8001 (MAGE-A1-directed TCR-transduced autologous CD8+ T-cells) in subjects with HLA-A*02:01 genotype and advanced stage/metastatic, MAGE-A1+ solid tumors (including but not limited to melanoma [skin or uveal], NSCLC, urothelial, breast, gastric [including gastroesophageal junction], esophageal, sarcoma, HNSCC, HCC, biliary tract, cervical, and salivary gland cancer) that either have no further approved therapeutic alternative or are not eligible for them or that are in a non-curable state as per the Investigator's assessment and have received a minimum of two lines of systemic therapy.

This two-part clinical trial will consist of a Phase 1 Part, which includes dose-escalation and expansion, and a Phase 2 Part.

In the Phase 1 Part dose-escalation, at least 6 subjects and up to 18 subjects (if DLT occurs) will receive escalating doses of TK-8001, with up to three dose levels explored. During the Phase 1 Part expansion, up to 20 additional subjects may be treated on DL3 if cleared during dose escalation to further evaluate the safety and efficacy of TK-8001 (Cohort 1).

An additional cohort of up to 10 subjects with brain metastases (Cohort 2) may also be treated on DL3 if cleared during dose-escalation. The maximum total number of subjects to be treated on DL3 during Phase 1 will be 33 subjects.

In the Phase 2 Part, up to 30 patients will receive TK-8001 to further evaluate the efficacy and safety of TK-8001 and to confirm the RP2D.

Both the Phase 1 Part and Phase 2 Part of the trial will consist of the following periods: Screening and Leukapheresis Period, Conditioning Period, TK-8001 Treatment Period, DLT Monitoring Period, Short-term Follow-up Period (Year 1), and Long-term Follow-up Period (Year 2 - 15).

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Brussel, Belgium, 1000
    • Universite Libre de Bruxelles (ULB) - Institut Jules Bordet Anderlecht
  • Brussels, Belgium, 1000
    • Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Institut Roi Albert II
  • Ghent, Belgium, 9000
    • University Hospital Ghent
  • Liège, Belgium, 4000
    • Centre Hospitalier Universitaire (CHU) de Liege
• Germany
  • Berlin, Germany, 12203
    • Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin
  • Frankfurt, Germany, 60590
    • Universitatsklinikum Frankfurt, Goethe Universitat
  • Munich, Germany, 81377
    • Klinikum der Universität München
  • Würzburg, Germany, 97080
    • Universitatsklinikum Wurzburg
  • Sachsen
    • Dresden, Sachsen, Germany, 01304
      • Technische Universität Dresden (TU Dresden)
• Netherlands
  • Amsterdam, Netherlands, 1066
    • the Netherlands Cancer Institute
• Spain
  • Barcelona, Spain, 08035
    • Hospital Universitario Vall d´Hebron
  • Madrid, Spain, 28050
    • START Madrid-HM CIOCC
  • Pamplona, Spain, 31008
    • Clinica Universidad de Navarra
• United Kingdom
  • Manchester, United Kingdom, M19 2WE
    • The Christie NHS Foundation Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Able to understand and comply with study procedures
• At least 18 years old
• Phase 1 Part dose-escalation and Phase 1 Part expansion Cohort 1 only: Presence of an advanced-stage/metastatic, solid tumor in non-curable state as per current medical knowledge, for which there is either no further approved therapeutic alternative available or the subject is not eligible for them or, for which the subject has completed a minimum of two lines of approved systemic therapy in the advanced-stage/metastatic setting.
• Phase 1 Part expansion Cohort 2 only: Presence of an advanced-stage/metastatic disease of the following indications: melanoma (skin or uveal), NSCLC, urothelial, breast cancer in non-curable state as per current medical knowledge, for which there is either no further approved therapeutic alternative available or the subject is not eligible for them or, for which the subject has completed a minimum of two lines of approved systemic therapy in the advanced-stage/metastatic setting.
• HLA-A*02:01 genotype.
• MAGE-A1+ tumor positive for MAGE-A1
• At least one measurable lesion, that can be accurately measured as per RECIST Version 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• Life expectancy > 3 months as assessed by the Investigator
• All toxicities related to prior therapy must have recovered to baseline or Grade ≤ 1 based on CTCAE v5.0
• Immune-related adverse events (irAEs) from previous therapies must have recovered to baseline or Grade ≤ 1

Exclusion Criteria:

• Any tumor-directed therapy within 14 days before start of conditioning therapy
• Any other MAGE-A1-targeting therapy.
• Pre-existing arrhythmia, uncontrolled angina pectoris, presently uncontrolled heart failure, or any myocardial infarction/coronary event as well as any thromboembolic event at any time < 6 months prior to screening.
• Left ventricular ejection fraction (LVEF) < 45% as measured by an echocardiogram
• History of CNS disease such as stroke, seizure, encephalitis, or multiple sclerosis (within 6 months prior to screening)
• Active allergy requiring continuous systemic medication or active infections requiring IV/PO anti-infectious therapy
• History of or clinical evidence of CNS primary tumors or metastases, unless they have been previously treated, and have been stable for at least 4 weeks prior to trial entry
• Major surgery within last 4 weeks prior to consent
• Active disease/ongoing infection with HIV, HBV, HCV, TB, syphilis, or SARS-CoV-2
• Receipt of any organ transplantation, except for transplants that do not require immunosuppression
• Any vaccine administration within 4 weeks of IP administration.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MAGE-A1 - directed TCR transduced autologous T-cells; Single-dose, intravenous infusion	Biological: Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR; Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Preliminary anti tumor activity	Evaluation of overall response rate (ORR), stable disease rate (SD), partial response rate (PR), and complete response (CR) rate of TK-8001 monotherapy, according to RECIST Version 1.1 and modified Response Evaluation Criteria in Solid Tumors (RECIST, V1.1) in cancer immunotherapy trials (iRECIST)	Up to 15 years after TK-8001 treatment, or until disease progression
Safety and tolerability	Incidence and grade of treatment-emergent adverse events (AEs) and serious adverse events (SAEs); Number and type of dose limiting toxicities (DLT)	Up to 15 years after TK-8001 treatment (1 year short-term follow-up, 14 years long-term follow up)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
End of dose escalation	RP2D will be determined through integrated evaluation of adverse events, serious adverse events, antitumoral activity, and evaluation of the biological and physiological effects of TK-8001 in the body.	28 days after TK-8001 treatment of last patient in Phase 1

Collaborators and Investigators

• Sponsor: T-knife GmbH
• Investigators: Study Director: Behzad K Masouleh, MD, PhD, T-knife GmbH

Study record dates

Study Major Dates

• Study Start (Actual): July 29, 2022
• Primary Completion (Actual): January 8, 2024
• Study Completion (Actual): January 8, 2024

Study Registration Dates

• First Submitted: June 1, 2022
• First Submitted That Met QC Criteria: June 23, 2022
• First Posted (Actual): June 24, 2022

Study Record Updates

• Last Update Posted (Actual): February 7, 2024
• Last Update Submitted That Met QC Criteria: February 5, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Advanced stage solid tumors; MAGE-A1; TCR-transgenic T-cells
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: TK-8001-01; 2021-004158-49 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No